The results of recent clinical trials in early diabetic nephropathy demonstrate that current therapies designed to suppress microalbuminuria do not prevent renal function decline. However, recent observational studies refined the traditional model of early nephropathy in type 1 diabetes and may inform more effective therapies for the prevention of chronic kidney disease.
Introduction
According to the traditional model of diabetic nephropathy in type 1 diabetes, the development of microalbuminuria alone is seen as the fundamental predictor of eventual advanced stage kidney disease. For that reason and because of efficacy in late-stage nephropathy, blockade of the renin-angiotensin-aldosterone system (RAAS) to suppress microalbuminuria was assumed to represent the effective strategy for early prevention of relevant clinical outcomes such as the advanced stages of chronic kidney disease [generally representing glomerular filtration rate (GFR) < 60 ml/min] and death. To the contrary, results of recent large-scale clinical trials are in direct opposition to this traditional view and thus force a critical review of the model and the therapies that arise from it [1,2 ,3 ].
Specifically, this review will place into context the evidence for a second fundamental phenotype of early nephropathy -termed early renal function decline (ERFD) -that, together with microalbuminuria, can further refine risk prediction of advanced stage kidney disease and possibly serve as a better proxy for diabetic kidney disease progression. On the basis of knowledge ascertained about the predictors of ERFD in the last year, speculation on more effective therapies for prevention of advanced stage kidney disease in type 1 diabetes will be made. Although there is limited knowledge about the natural history of ERFD in type 2 diabetes, we postulate that the conclusions inferred for type 1 diabetes may also apply to type 2 diabetes.
The contemporary model of nephropathy in type 1 diabetes
Microalbuminuria has become firmly entrenched as the primary predictive marker of risk for the advanced stages of chronic kidney disease. In effect, the origins of this model can be traced to three follow-up studies published in the 1980s [4] [5] [6] . Patients with microalbuminuria, defined by persistent urinary albumin excretion approximately in the range of 30-300 mg/min, were followed for 7-14 years and advanced nephropathy developed in 60-90% of them. In retrospect, interpretation of the evidence could have been more cautious. Collectively, the three studies included only 30 patients and the outcome was based on a surrogate marker, the progression of microalbuminuria to proteinuria (frequently referred to as 'macroalbuminuria'). The presumed association of renal function impairment with proteinuria gave plausibility to a simple model of diabetic nephropathy comprising three sequential stages: microalbuminuria heralds proteinuria, which in turn initiates the process of renal function loss to end-stage renal disease [7] .
As an extension of this traditional model, therapy in patients with microalbuminuria became focused on the prevention of proteinuria through blockade of the RAAS [8, 9] . However, that the progression of microalbuminuria to proteinuria was seen as the proxy for declining renal function was a premature conclusion. Contrary to the three early studies that viewed microalbuminuria as the committed step toward advanced stage kidney disease, it came to be seen as a dynamic process that was more likely to remit to normoalbuminuria than to progress to proteinuria [10] [11] [12] [13] . Reinforced by more recent results from the Oxford Regional Prospective Study in which the majority (52%) of patients with microalbuminuria had a dynamic process described as 'intermittent microalbuminuria' [14] , the 6-year cumulative incidence of remission is now accepted to be approximately 50% [10] [11] [12] . This risk of remission far outweighs the risk of progression to proteinuria observed in epidemiological studies (15-25%) or clinical trials [10] [11] [12] [14] [15] [16] [17] .
Early renal function decline forms the basis of a new model of early nephropathy
Although microalbuminuria is of fundamental importance to the model of early diabetic nephropathy, in view of the frequent occurrence of microalbuminuria remission and low risk of progression to proteinuria, it can no longer be seen as the independent predictive marker for the advanced stage of chronic kidney disease in the contemporary model. The last year of the early nephropathy literature has provided major insight into the early natural history of diabetic nephropathy in type 1 diabetes and has identified a new phenotype -ERFD [18 ,19-22] .
To better understand what is meant by ERFD, one must recall that the assessment of a patient's renal function may be used for two different purposes. One is to diagnose impaired renal function, whereas the other is to detect the presence of a progressive loss of GFR over time even if it remains in the normal range (ERFD) [23] . The first is a cross-sectional assessment at a particular moment, and thus the identification of impaired renal function (typically considered to be less than 60 ml/min/ 1.73 m 2 ) serves only to recognize disease at a late stage [24] . The second, and most clinically relevant for disease prevention, is a longitudinal assessment to detect sys-tematic decreases in GFR and requires repeated measurements over time. The most important result is whether a downward trend (slope) is present, regardless of the initial GFR value [23, 25] .
Consistent with earlier reports [26, 27] , a recent report from the Pittsburgh Epidemiology of Diabetes Complications Study demonstrated that nearly 10% of cases with incident microalbuminuria already had frankly impaired renal function at the time of microalbuminuria onset, indicating that this process of renal function decline might precede even the onset of microalbuminuria [28] . Although this report emphasized that all patients with end-stage renal disease had previously developed proteinuria, it did not address the issue of timing of the process of initiation of renal function loss relative to microalbuminuria. To explore this relationship, a specific kind of cohort is needed -one in which renal status is evaluated at the onset of microalbuminuria, as absence of this evidence would compromise the assessment of renal function changes after the onset of microalbuminuria. A collection of prevalent cases detected by a single screening examination would not only lack this information but also would be biased by the underrepresentation of patients with rapidly progressive urinary albumin excretion.
Guided by these methodological considerations, a cohort of patients with type 1 diabetes and normoalbuminuria was monitored for the onset of microalbuminuria through the first Joslin Kidney Study on the Natural History of Microalbuminuria in Type 1 Diabetes. Seventy-nine participants who developed microalbuminuria during the first 4 years of follow-up were subsequently monitored for 12 years to characterize the longitudinal changes of albumin excretion and of renal function [29] . The 12-year risk of advanced stage kidney diseasecorresponding to stages 3-5 of chronic kidney disease (GFR MDRD < 60 ml/min) -was exceedingly high (29%). However, nearly half of the cases never developed proteinuria, and, in those cases that did, the vast majority began to lose renal function years prior to the development of proteinuria independent of such factors as the use of angiotensin-converting enzyme inhibitor agents. That renal function appeared to begin its decline as early as the onset of microalbuminuria in a substantial subset of patients necessitated a systematic study of GFR using a method that would be simple enough for epidemiological study, yet not hindered by the inaccuracy inherent in creatinine-based techniques when GFR is normal or elevated as it is in patients with type 1 diabetes with early nephropathy.
Cystatin C as a marker of glomerular filtration rate
Cystatin C is an endogenously produced nonglycosylated protease inhibitor that has characteristics that make it a desirable marker for renal function [30] [31] [32] [33] [34] . The accuracy of serum cystatin C for detecting the slope of GFR over time in patients with normal or elevated GFR has been well validated [34, 35] . Two very important aspects of the performance of serum cystatin C were demonstrated in these studies. First, they confirmed cross-sectional correlation of cystatin C with iothalamate clearance across the full range of GFR values. Second, and of greater importance, they demonstrated the validity of serial measures of cystatin C for measuring the slope of GFR over time -the correlation between the slopes of GFR change per year as estimated by cystatin C and iothalamate clearance is very high, whereas it is poor for the creatinine-based estimates including the Cockroft-Gault and the Modification of Diet in Renal Disease (MDRD) equations [34] . To illustrate the performance of cystatin C, a representative example is shown in Fig. 1 from a study conducted in the Diabetic Renal Disease Study [34, 36] .
Microalbuminuria and the risk of early progressive renal function decline in type 1 diabetes
To determine the precise timing of renal function decline relative to the onset of microalbuminuria -and specifically if it could begin in patients with longstanding normoalbuminuriaorinpatientswithmicroalbuminuria -the Joslin investigators measured serial determinations of GFR estimated by serum cystatin C (GFR cystatin C ) in 301 patients with microalbuminuria (a mixed population of prevalent and incident cases) and compared these with a control population of 268 patients with longstanding normoalbuminuria [18 ] . It was first observed that the trends in GFR cystatin C were linear, regardless of whether renal function appeared to be stable or rapidly declining. Figure 2 demonstrates the fundamental finding from the study. It plots the distribution of the annual percentage change in GFR cystatin C for each individual according to the two groups studied: patients with longstanding normoalbuminuria (the distribution shown on the left side of the plot) compared with patients with microalbuminuria (shown on the right side of the plot). The horizontal line represents the threshold (À3.3%/year) beyond which the annual percentage loss in GFR is predicted to be abnormally rapid. As the reference distribution for evaluating whether a negative slope or trend in renal function qualified as an abnormal rate of decline, the longitudinal data available from the Baltimore Aging Study were used [37] . Using the weighted mean and variances for the participants aged 30-59.9 years, the range that included 95% of the distribution (À3.3 to þ2.8%/year) was determined, and the 2.5th percentile (the lower limit) was selected as the threshold to define cases of ERFD [37] . Although 9% of those with longstanding normoalbuminuria had ERFD by this definition, the magnitude of Aug-1990
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decline was small. In contrast -and contrary to the old model of nephropathy in which renal function was believed to decline only after exposure to proteinuriaone-third (31%) of those with microalbuminuria had ERFD and many had dramatic rates of decline approaching 25%/year [18 ] . The risk of ERFD was strongly related to the early course of urinary albumin excretion as shown in Fig. 3 . For example, those who experienced regression of microalbuminuria had the lowest risk, whereas those whose microalbuminuria progressed had the highest. Overall, however, the one-third of individuals with microalbuminuria who subsequently developed ERFD could not be determined by assessment of urinary albumin excretion alone.
Taken together with the data on microalbuminuria, a new model for diabetic nephropathy emerges: first, the onset of microalbuminuria is a dynamic process in which remission to normoalbuminuria is the most common course after onset. Second, even as early as the onset of microalbuminuria, ERFD is initiated in a third of patients with new onset microalbuminuria. This ERFD is a progressive, linear process that leads to impaired renal function in a subset regardless of the course of urinary albumin excretion. Although it is not clear whether the onset of microalbuminuria causes ERFD, the initiation of the process certainly does not depend on proteinuria as previously thought. These new observations on the natural history of early nephropathy raise the possibility that urinary albumin excretion and ERFD may represent parallel phenotypes that only share in part the same etiologic mechanisms.
Interpretation of recent clinical trial results in the context of the contemporary model
Of fundamental importance in assessing the validity of the new model of diabetic nephropathy is the evaluation of its consistency with the results of clinical trials. First, the notion that remission of microalbuminuria requires 4 years to observe the natural history of its nonlinear rise and fall indicates that clinical trials evaluating change in urinary albumin excretion need to be of at least this duration. Studies that are of this sufficient duration are uncommon and demonstrate much less suppression of urinary albumin excretion than those that are of shorter duration [8] . Secondly, recent clinical trial evidence strongly suggests that agents that inhibit the RAAS, while they may suppress urinary albumin excretion in the relative short term, may not prevent renal function decline and the development of advanced stage kidney disease. For example, a meta-analysis of nine studies (with 23 study groups) derived from randomized, blinded clinical trials of type 1 diabetes patients with microalbuminuria failed to demonstrate a beneficial effect on the annual percentage change in GFR despite significant suppression of microalbuminuria by way of agents that inhibit the RAAS (Fig. 4) [2 ]. In addition, the results of the landmark renin-angiotensin study were recently presented in a late-breaking clinical trials session [1]. In this multicenter randomized controlled trial, 285 normoalbuminuric patients with type 1 diabetes underwent renal biopsy before and after randomization to placebo, angiotensin-converting enzyme inhibitor therapy, or angiotensin receptor blockade for 5 years. The primary outcome of change in the glomerular mesangial fractional volume (the strongest predictor of renal function loss) was similar in all groups, indicating that, in this patient population, renin-angiotensin system study (RASS) inhibition does not influence the gold standard morphological measures of early nephropathy despite suppression of urinary albumin excretion. Finally, though by analogy in type 2 diabetes, the results of the ONgoing Telmisartan Alone in combination with Ramipril Global Endpoint Trial (ONTARGET) study disagree entirely with the traditional model in which augmented RAAS inhibition should equate to improved clinical outcomes [3 ] . In this 4.5-year study, examining as predefined primary renal outcome the combination of dialysis, doubling of creatinine, and death, 25 620 high vascular risk participants (of whom 9612 had diabetes) were randomized to angiotensinconverting enzyme inhibitor therapy, or angiotensin receptor blockade, or both. A statistically significant increase in the primary renal outcome was observed on combination Regression is defined as a halving (decrease by 50% or more) of the urinary albumin excretion rate (in mg/min) (N ¼ 100). Stable is defined as no change greater than a halving or doubling of the urinary albumin excretion rate (N ¼ 121). Progression is defined as a doubling (increase by 100% or more) of the urinary albumin excretion rate (N ¼ 58). Twentytwo patients had insufficient urine samples in the second follow-up interval to determine the course of their microalbuminuria. Adapted from [18 ] .
therapy (hazard ratio 1.09, 1.01-1.18; P ¼ 0.037 versus angiotensin-converting enzyme inhibitor) [3 ] .
The traditional model of early diabetic nephropathy cannot reconcile these consistent discrepancies between suppression of urinary albumin excretion and improvements in either morphological or renal function measures. Rather, they highlight the messages inherent in the new model of diabetic nephropathy that views ERFD as a fundamental phenotype. Although ERFD is initiated at the onset of microalbuminuria and is only moderately correlated with the course of albumin excretion, it appears to represent pathological mechanisms that are distinct to those that promote progression or regression of urinary albumin excretion.
Future directions: therapy to prevent and treat early renal function decline
That the course of microalbuminuria occurs in parallel with ERFD without strong evidence for a causal relationship implies that therapies designed to reduce urinary albumin excretion may not have the same beneficial effect on renal function at this early stage of nephropathy. Furthermore, despite the short-term reduction in albumin excretion from RAAS inhibition, this therapy does not appear to attenuate ERFD as it does in late-stage nephropathy. These observations highlight the need to evaluate the effect of current and emerging therapies on ERFD instead of its impact only on the legacy marker, reduction of urinary albumin excretion. Knowledge of the determinants of ERFD may inform therapies to prevent loss of renal function regardless of effect on urinary albumin excretion. To date, determinants with potential etiologic implications for ERFD include markers of protein glycation; uric acid metabolism; and low-grade chronic inflammation.
Although protein glycation damage, such as the formation of advanced glycation end products, has long been recognized as a fundamental mechanism of cellular injury in diabetes [38] , knowledge of the relative contribution of specific glycation damage mechanisms on microalbuminuria versus ERFD has not been recognized until recently.
Early nephropathy in type 1 diabetes Perkins and Krolewski 237 In a study comprising participants from the first Joslin Kidney Study with new onset microalbuminuria and normoalbuminuria, the urine and plasma ultrafiltrate samples were examined for adducts of oxidative, nitrative, and glycation protein damage by an advanced liquid chromatography-tandem mass spectrometry technique [39] . The fractional urinary excretions of two specific glycation adducts [pentosidine, a fluorophore, and N v -carboxy methylarginine (CMA), a hydroimidazolone advanced glycation end product] were elevated in patients prior to development of ERFD as compared with those whose renal function was stable over 10-year follow-up. This association was observed to be independent of HbA1c, the level of albumin excretion, and the levels of the other 10 adducts studied [39] . Although the precise etiological roles of pentosidine and CMA are not understood, the main implication of this finding is that increased urinary fractional excretion of these protein glycation adducts may represent a pathogenic mechanism unique to ERFD, distinct from those mechanisms involved in abnormal urinary albumin excretion.
Serum uric acid, the main byproduct of purine metabolism, has received renewed attention as having a potential causal role in renal function impairment, possibly owing to its prooxidant, complement system activation, RAAS upregulation, and nitric oxide inhibitory mechanisms rather than its role as a marker of renal function itself [40] [41] [42] [43] [44] . In the second Joslin Kidney Study on the Natural History of Microalbuminuria in Type 1 Diabetes, a cohort of 675 patients with normoalbuminuria or microalbuminuria and estimated GFR generally above 90 ml/min, serum uric acid was the variable most strongly associated with the level of GFR, independent of its association with urinary albumin excretion, age, sex, HbA1c, and antihypertensive medication use [20] . Uric acid levels in this study were not in the hyperuricemic range -rather, even high normal levels were found to relate to GFR reductions. As observed with markers of protein glycation, the independent association of subtle change in uric acid with the cross-sectional level of GFR within the normal range provides even further support for the existence of mechanisms for microalbuminuria and ERFD that may be distinct from one another [20, 21] .
Recent publications have strongly supported the role of chronic inflammation and apoptosis in the pathogenesis of progressive urinary albumin excretion in diabetic nephropathy [45] [46] [47] [48] . The association of inflammatory markers with renal function, however, was also recently reported in both longitudinal and cross-sectional studies.
In an analysis of baseline urine samples from participants in the longitudinal first Joslin Kidney Study, three study groups were investigated: those with microalbuminuria and ERFD, those with microalbuminuria only, and those with neither [19] . The urinary levels of five inflammatory markers measured at baseline were significantly higher for those with future ERFD: interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1, interferon-gammainducible protein (IP-10), and macrophage inflammatory protein-1d. Multivariate analysis revealed that those with more than two elevated markers were more than five times as likely to have subsequent ERFD. Additionally, cross-sectional analyses of the level of GFR and serum concentrations of inflammatory markers were investigated in the second Joslin Kidney Study. In these analyses, two classes of soluble markers of the tumor necrosis factor (TNF)-a pathway -TNF receptors and the soluble form of Fas -had association with the level of GFR within its normal range, independent of age and the level of urinary albumin excretion [22] .
Although requiring further study, collectively these data suggest that therapy designed to modify processes of protein glycation, uric acid metabolism, and chronic inflammation may be found to have an impact on changes in early renal function rather than the specific pathogenic mechanisms involved in preventing abnormalities in urinary albumin excretion. As an example, the use of drugs such as allopurinol or probenecid for modification of serum uric acid may hold promise as therapy for the prevention of ERFD in early nephropathy [20, 44] . This will require confirmation in prospective studies that measure ERFD with the use of a valid marker of renal function when in the normal or elevated ranges, such as the serial measurement of serum cystatin C.
Conclusion
A contemporary model of early nephropathy has emerged from studies in type 1 diabetes in which the onset of microalbuminuria is characterized by frequent remission to normoalbuminuria. During this time, regardless of the course of albumin excretion, a subset of approximately a third of individuals will initiate a process of ERFD to advanced stages of chronic kidney disease. The existence of pathogenic mechanisms for the two independent early phenotypes -microalbuminuria and ERFD -is further supported by the findings of recent clinical trials that imply that therapy that successfully suppresses urinary albumin excretion may not have an impact on ERFD. In view of the recent observational studies and clinical trial results summarized in this review, progressive urinary albumin excretion on its own may no longer be accepted as a proxy for the risk of advanced kidney disease. Furthermore, given the independence of the microalbuminuria and ERFD phenotypes, therapies that have failed to demonstrate consistent efficacy in clinical studies of progressive urinary albumin excretion -such as glycosaminoglycans [49] or inhibitors of protein kinase C b [50] -should be considered for their effect on ERFD using an outcome measure such as serial determinations of serum cystatin C.
Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 272-273). 28:614-627. This 4.5-year randomized, controlled trial of 25 620 high-risk vascular patients (including 9612 with diabetes) comparing ramipril, telmisartan, or a combination of these two RAAS inhibiting agents examined as predefined primary renal outcomes the combination of dialysis, doubling of creatinine, and death. A statistically significant increase in the primary renal outcome was observed on combination therapy (hazard ratio 1.09, 1.01-1.18; P ¼ 0.037 versus angiotensin-converting enzyme inhibitor), indicating that therapy designed to reduce urinary albumin excretion may not prevent renal function loss as suggested by the traditional model of diabetic neuropathy.
